VectorY
Dr. Pavlina Konstantinova has eighteen years of experience in gene therapy. Dr. Konstantinova is a founder and Chief Scientific Officer of VectorY. Previously, she was a Vice President Research at uniQure, overseeing the development of multiple programs, and bringing the first AAV gene silencing platform in Huntington’s disease to the clinic.
This person is not in any offices
VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide.